Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) have been assigned a consensus rating of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $77.63.
AERI has been the subject of several research analyst reports. Canaccord Genuity set a $86.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 15th. Zacks Investment Research raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 17th. Seaport Global Securities reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Monday, March 5th. BidaskClub raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, HC Wainwright set a $78.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 1st.
Aerie Pharmaceuticals traded up $3.10, hitting $70.45, during trading on Friday, according to MarketBeat Ratings. The stock had a trading volume of 1,200,805 shares, compared to its average volume of 366,438. The company has a debt-to-equity ratio of 0.52, a current ratio of 13.57 and a quick ratio of 13.53. The company has a market cap of $2.60 billion, a P/E ratio of -20.91 and a beta of 0.94. Aerie Pharmaceuticals has a one year low of $47.05 and a one year high of $71.30.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, May 8th. The company reported ($0.83) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.04. equities research analysts expect that Aerie Pharmaceuticals will post -3.75 EPS for the current year.
In other Aerie Pharmaceuticals news, Director Gerald D. Cagle acquired 1,000 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The shares were bought at an average cost of $50.25 per share, with a total value of $50,250.00. Following the completion of the acquisition, the director now directly owns 15,050 shares in the company, valued at approximately $756,262.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vicente Anido, Jr. sold 150,000 shares of Aerie Pharmaceuticals stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $62.28, for a total transaction of $9,342,000.00. Following the transaction, the chief executive officer now directly owns 176,320 shares in the company, valued at $10,981,209.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 263,708 shares of company stock worth $16,249,556. 10.53% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of AERI. QS Investors LLC purchased a new position in Aerie Pharmaceuticals during the fourth quarter valued at approximately $125,000. Public Employees Retirement Association of Colorado purchased a new position in Aerie Pharmaceuticals during the fourth quarter valued at approximately $176,000. Xact Kapitalforvaltning AB purchased a new position in Aerie Pharmaceuticals during the first quarter valued at approximately $258,000. Bamco Inc. NY increased its holdings in Aerie Pharmaceuticals by 19.4% during the fourth quarter. Bamco Inc. NY now owns 7,351 shares of the company’s stock valued at $439,000 after buying an additional 1,195 shares during the period. Finally, Summit Trail Advisors LLC increased its holdings in Aerie Pharmaceuticals by 4,034.9% during the first quarter. Summit Trail Advisors LLC now owns 439,911 shares of the company’s stock valued at $440,000 after buying an additional 429,272 shares during the period.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.